RECOMBITEK® Equine West Nile Virus contains a lyophilized recombinant canarypox vectored West Nile Virus vaccine plus a sterile liquid diluent. A canarypox vector has been modified using recombinant technology to express the desired antigens capable of stimulating a protective immune response to West Nile Virus. After inoculation, the vector does not multiply in the horse, but does express the protective proteins. As a consequence, these components induce an immune status against West Nile Virus. Safety and immunogenicity of this vaccine have been demonstrated by vaccination and challenge tests in susceptible horses.
Directions:
Reconstitute the lyophilized vaccine with accompanying liquid diluent and aseptically inject a 1 ml dose by intramuscular route. For primary vaccination, revaccinate with a second 1 ml dose of this product 4 to 6 weeks later. Annual revaccination with a single dose is recommended.
Recombitek Equine West Nile Virus
